Welcome to our dedicated page for CRISPR Therapeutics SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
A shareholder filed a Rule 144 notice to sell 34,972 shares of common stock through Morgan Stanley Smith Barney on or about January 22, 2026 on NASDAQ. The planned sale has an aggregate market value of $2,105,069.60.
The shares to be sold were acquired on January 22, 2026 via a stock option exercise, paid for in cash. Shares of the issuer outstanding were 95,300,233 at the time of the notice; this is a baseline figure, not the amount being sold.
Over the prior three months, the same seller, Raju Prasad, reported additional common share sales of 10,000 shares for $559,548.00 on December 22, 2025 and 29,700 shares for $1,786,635.87 on January 6, 2026.
A holder of common stock in CRSP has filed a notice of proposed resale under Rule 144. The filing covers the planned sale of 30,000 shares of common stock through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $1,578,300. The shares are part of a larger base of 95,300,233 common shares outstanding.
The securities to be sold were acquired as compensation through restricted stock awards from the issuer in multiple grants dated between 2018 and 2025, each labeled as compensation on the acquisition and payment dates. The person for whose account the sale is to be made represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
CRISPR Therapeutics AG filed an update on multiple gene-editing programs across cardiovascular, autoimmune, oncology and regenerative medicine. The company highlighted continued progress with its in vivo programs using a proprietary lipid nanoparticle delivery platform, including CTX310, which in 2025 showed deep and durable reductions in triglycerides and LDL after a single intravenous dose with a well‑tolerated safety profile and has moved into Phase 1b trials.
CTX320, targeting LPA, has shown reductions of up to 73% in a dose‑escalation trial, while next‑generation candidate CTX321 with about two‑fold greater preclinical potency is in IND/CTA‑enabling studies. Additional preclinical assets include CTX460 for alpha‑1 antitrypsin deficiency and CTX340 for refractory hypertension. Zugocabtagene geleucel (zugo‑cel) is in Phase 1 autoimmune trials where early systemic lupus erythematosus patients achieved drug‑free remission or full score improvement, and an oncology trial is ongoing alongside a new collaboration with Eli Lilly. In regenerative medicine for diabetes, CTX211 data with detectable C‑peptide at 12 months support a move to next‑generation candidate CTX213.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised stock options for 29,700 Common Shares on January 6, 2026 at exercise prices of $45.15 and $44.31 per share, then sold 29,700 Common Shares at weighted average prices of $60.1799, $60.0000 and $60.2134 per share under a Rule 10b5-1 trading plan adopted on August 18, 2025. Following these transactions, he directly holds 84,132 stock options and 6,767 Common Shares.
Raju Prasad filed a notice of proposed sale of the issuer’s common stock under Rule 144. The planned transaction covers 29,700 common shares, to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,786,635.87, based on information in the filing. The shares relate to a stock option exercise on 01/06/2026, paid in cash the same day, and are expected to be sold around 01/06/2026 on the NASDAQ market, where 95,300,233 shares of this class are outstanding.
The filing also reports that over the prior three months, Prasad sold 10,000 common shares on 12/22/2025 for $559,548.00. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
CRISPR Therapeutics AG’s Chief Financial Officer, who files individually, reported automatic sales of company stock. On December 22, 2025, the officer sold a total of 10,000 common shares of CRISPR Therapeutics AG in three separate transactions, at weighted average prices of $55.1022, $56.3345, and $56.8858 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, which is designed to provide an affirmative defense for insiders trading under predetermined instructions. After these sales, the officer beneficially owns 6,767 common shares directly.
CRISPR Therapeutics AG reported a wider quarterly loss as collaboration and R&D spending remained high. For Q3 2025, total revenue was $0.9 million from grants, while operating expenses reached $132.9 million, driven by $58.9 million in research and development and $57.1 million in collaboration expense, net. Net loss was $106.4 million (basic and diluted loss per share $1.17).
Year to date, the company recorded a $451.0 million net loss, including $96.3 million of acquired in‑process R&D tied to the Sirius collaboration. Liquidity remained strong with $286.5 million in cash and cash equivalents and $1,629.2 million in current marketable securities, plus $28.4 million non‑current. Shareholders’ equity stood at $1.916 billion. The company continued equity financing, issuing 5.1 million shares under its 2021 ATM for $286.8 million in net proceeds, and later launched a new 2025 ATM. As of September 30, 2025, 93,872,794 common shares were outstanding.
CRISPR Therapeutics AG furnished a Form 8‑K announcing its financial results for the quarter ended September 30, 2025. The company provided the full details in a press release attached as Exhibit 99.1 under Item 2.02.
The materials are furnished, not filed, and therefore are not subject to Section 18 liabilities or incorporated by reference except as specifically stated. The 8‑K was signed by CEO Samarth Kulkarni, Ph.D., on November 10, 2025.
CRISPR Therapeutics (CRSP) Form 4: On October 16, 2025, the CEO and director reported the vesting and settlement of 100,000 restricted stock units into common shares. On October 17, 2025, 50,895 common shares were sold at $67.91 to cover tax withholding mandated by company policy. Following these transactions, holdings were 254,201 common shares directly and 85,662 indirectly via The Kulkarni 2023 GRAT. The RSU grant leaves 300,000 RSUs scheduled to vest annually through October 2028.
CRISPR Therapeutics (CRSP) reported an insider equity event. The company’s General Counsel and Secretary had 2,114 restricted stock units settle into common shares on 10/13/2025. On 10/14/2025, 1,076 shares were sold at $66.6 to cover tax withholding under the company’s RSU Settlement Policy, described as a non-discretionary sale.
Following these transactions, the insider directly owned 83,402 common shares. A remaining balance of 2,113 RSUs is reported outstanding.